Ausgabe 2/2023
Inhalt (8 Artikel)
The role of alternative splicing in lung cancer
Xuelian Ning, Zitong Fu, Jing Zhang, Shuangshu Gao, Zihan Cui, Mingqi Cong, Qingyu Guo, Xixi Sun, Jing Li, Minghui Zhang, Shuoshuo Wang
Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies
Alexis C. Boulter, Barry J. Maurer, Meredith Pogue, Min H. Kang, Hwangeui Cho, Amanda Knight, C. Patrick Reynolds, Donald Quick, Sanjay Awasthi, David E. Gerber
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
Sarina A. Piha-Paul, Chieh Tseng, Hai T. Tran, Meng Gao, Daniel D. Karp, Vivek Subbiah, Apostolia Maria Tsimberidou, Jitesh D. Kawedia, Siqing Fu, Shubham Pant, Timothy A. Yap, Van K. Morris, Bryan K. Kee, Mariela Blum Murphy, JoAnn Lim, Funda Meric-Bernstam
Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling
Xinghua Zhou, Jian Kang, Liangliang Zhang, Yue Cheng
Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: a pilot study
Mohsen Shafiei, Peter Galettis, Philip Beale, Stephanie E. Reuter, Jennifer H. Martin, Andrew J. McLachlan, Prunella Blinman
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study
Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P. Safran, Laura Nadeau, William J. Edenfield, Lionel D. Lewis, Dinko Rekić, Corina Dota, Lone H. Ottesen, Yan Li, Ganesh M. Mugundu
A case report of typhlitis during novel use of ropidoxuridine–capecitabine–radiotherapy for treatment-naïve rectal cancer
Charles A. Kunos, Richard Piekarz, Jerry M. Collins, Timothy J. Kinsella